Harrow 10-Q: Record Q3 Revenue $99.3M, $9.8M Net Income; VEVYE Licensor Consent Risk on TYRVAYA
HROW sits 24% above its 52-week low of $25.76 on elevated volume (2.0× avg).
Summary
Harrow's Q3 10-Q confirms $99.3M revenue and $9.8M net income, but discloses a nine-month net loss of $35.1M, $27.4M of operating cash burn, and an unresolved VEVYE licensor consent issue that could force a TYRVAYA divestiture.
Key Events · Earnings and Guidance · HROW
-
Q3 Revenue Jumps to $99.3M
Total revenue rose to $99,297,000 from $71,638,000 a year earlier, with VEVYE at $39,699,000 and TRIESENCE at $10,707,000; Q3 net income was $9,757,000, or $0.25 diluted per share.
-
Nine-Month Loss and Cash Burn
Through September 30, 2026 the company posted a net loss of $35,115,000 and used $27,363,000 of cash in operations, versus $35,453,000 provided in the prior-year period, driven largely by a $38,970,000 receivables build.
-
VEVYE Licensor Consent Unresolved
A new risk factor states the VEVYE licensor has not agreed the dry-eye exclusivity restriction permits TYRVAYA; absent an arrangement, Harrow may need to divest TYRVAYA within a period generally of twelve months and could still owe up to $70,000,000 in milestones unless assumed.
-
TYRVAYA 2027 Guidance
Management expects TYRVAYA to contribute in excess of $30,000,000 of revenue in 2027 with approximately $20,000,000 of new annual operating expenses, and does not expect the first net sales milestone to be achieved.
Analysis · HROW · Life Sciences
The 10-Q confirms the swing to profitability the 8-K flagged this morning, but it also surfaces two things the headline release did not: a nine-month net loss of $35.1M with $27.4M of operating cash burn, and a new risk factor saying the VEVYE licensor has not agreed that its dry-eye exclusivity restriction permits the TYRVAYA acquisition. If that dispute is not resolved, Harrow may have to divest TYRVAYA within roughly twelve months while still owing up to $70M in contingent milestones unless a buyer assumes them. Against that, management guides TYRVAYA to more than $30M of 2027 revenue at a cost of about $20M in new annual operating expense.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HROW was trading at $31.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $25.76 to $54.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.